Search

Your search keyword '"Musiime, Victor"' showing total 559 results

Search Constraints

Start Over You searched for: Author "Musiime, Victor" Remove constraint Author: "Musiime, Victor"
559 results on '"Musiime, Victor"'

Search Results

1. Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial.

3. First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia.

7. Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: study protocol for a multicenter, open-label randomized controlled clinical trial

12. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

13. Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review

14. Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial

16. Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub‐study of the ODYSSEY randomized controlled trial

17. Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list.

19. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

20. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

21. What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies

24. Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial

25. Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV.

27. High Incidence of Refeeding Syndrome during the Transition from F75 to Ready‐to‐Use Therapeutic Feeds among Children 6 to 59 Months with Severe Acute Malnutrition at the Pediatric Nutritional Unit of Mulago Hospital.

28. HIV prevalence among children admitted with severe acute malnutrition and associated factors with mother-to-child HIV transmission at Mulago Hospital, Uganda: A mixed methods study

32. PA-655 Severe pneumonia is associated with worse neurocognitive function among infants living with HIV

33. OA-429 High mortality in African infants living with HIV hospitalized with severe pneumonia

34. PA-675 Navigating the COVID-19 pandemic for participant recruitment and follow-up: experiences from the PediCAP clinical trial consortium

35. OA-286 Plasma concentrations of first line antituberculosis drugs in infants with HIV and severe pneumonia: a pharmacokinetic sub-study of the empirical trial

39. The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa

40. Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list

41. Impact of COVID-19 on Well-Being and Physical Activity in Ugandan Children With and Without HIV.

42. Population Pharmacokinetics of Pediatric Lopinavir/Ritonavir Oral Pellets in Children Living with HIV in Africa.

43. Activated NK Cells with Pro-inflammatory Features are Associated with Atherogenesis in Perinatally HIV-Acquired Adolescents

44. 93 Acceptability and Usability of Tablet-Based Neuropsychological Tests among South African and Ugandan Adolescents With and Without HIV

48. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

49. Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial

50. Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial

Catalog

Books, media, physical & digital resources